LV 305

Drug Profile

LV 305

Alternative Names: Cancer vaccine DCVex NY-ESO-1 - Immune Design; DCVex™/NY-ESO-1 cancer vaccine - Immune Design; ID-LV305; LV 305

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Design
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Solid tumours

Most Recent Events

  • 05 Jun 2017 Immunogenicity data from a phase I trial in Solid tumours presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 30 May 2017 Immune Design completes enrolment in its phase I trial for Solid tumours (Monotherapy, Locally recurrent, Metastatic disease, In adults, In elderly) in USA (NCT02387125)
  • 08 Jun 2016 Interim data from a phase I trial in Sarcoma presented at 52nd Annual Meeting of the American Society of Clinical Oncology 3 - 7 Jun 2016 (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top